Quatrefolic® 360° collection in video will present you the wide range of application where folate supplementation may be beneficial.
Watch the first episode is out now!
At Gnosis by Lesaffre, we’re committed to supporting women’s health and wellness especially during pregnancies.
To this end, we developed and patented Quatrefolic®, the 5-MTHF glucosamine salt.
In the first issue of our Quatrefolic® 360° collection video, discover how Quatrefolic® may support the early stages of pregnancy when the need for folate increases as the body needs more resources to help fetal development. By offering an active form of folate and not depending on the MTHFR enzyme, Quatrefolic® may appear as the right nutritional folate support, suitable for 100% of its consumers.
Want to learn more? Follow us on our YouTube channel to be sure not to miss the next episode.
DISCOVER ALL OUR LATEST NEWS
Biotic Live: A Successful First Edition Exploring the Power of Probiotic Yeasts
Gnosis by Lesaffre recently hosted the first edition of Biotic Live, a unique event dedicated to exploring the potential of probiotic yeasts. This live session brought together leading experts to present the latest scientific insights and real-world applications of live yeasts in human health.
Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day
At the recent Innovation Day seminar hosted by Complementary Medicines Australia (CMA), Gnosis by Lesaffre, led by Jose Pinedo Rivera, Product Manager, had the opportunity to present MyCondro™ to an engaged audience of over 250 industry professionals. The session, titled “Keeping Pace with a Changing World: MyCondro™ Disrupts the Chondroitin Sulfate Market,” was well received, sparking interest and conversations around the future of joint health solutions.
Supplementation with Menaquinone-7 (as MenaQ7®) Slows the Progression of Coronary Artery Calcification
The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery Calcification: A Randomized, Placebo-Controlled Trial,” were presented at the 34th European Meeting on Hypertension and Cardiovascular Protection, organized by the European Society of Hypertension (ESH), held in Milan in May 23–26, 2025.
